Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.
Feature|Articles|August 1, 2025
Are Benadryl-Associated Toxicities Enough to Pull It From Shelves?
Author(s)Ashley Gallagher, MA
Experts call for the review of diphenhydramine and its possible replacement with second-generation antihistamines that have similar efficacy with fewer adverse events.
Advertisement
Advertisement
In September 2020, the FDA issued a statement about the “Benadryl Challenge,” which includes ingesting high doses of Benadryl to induce hallucination and posting a video to TikTok, due to adolescents overdosing and subsequently dying.1 In the statement, the FDA warns that "taking higher than recommended doses of the common over-the-counter (OTC) allergy medicine diphenhydramine (Benadryl) can lead to serious heart problems, seizures, coma, or even death.”2
Related to this article
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Pharmacist-backed picks help families manage fever and pain, seasonal allergies, and cough and congestion as kids head back to the classroom.
In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
Advertisement
Advertisement